Răzvan Ionuț Văduva

Dr. Răzvan Ionuț Văduva

Urology, Spitalul Clinic de Urgenta Sfantul Ioan, Bucharest, Bucureşti, Romania
orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
Catalin Andrei BulaiCatalin Andrei Bulai
Catalin Andrei Bulai
RSRazvan Andrei Stoica
Razvan Andrei Stoica
AMADRIAN MILITARU
ADRIAN MILITARU
APAna Maria Punga
Ana Maria Punga
Răzvan Ionuț VăduvaRăzvan Ionuț Văduva
Răzvan Ionuț Văduva
Bogdan Florin GeavleteBogdan Florin Geavlete
Bogdan Florin Geavlete
Prostate cancer diagnostics have evolved substantially with the integration of multiparametric magnetic resonance imaging (mpMRI), refined prostate-specific antigen (PSA) metrics, and targeted biopsy techniques. While mpMRI has become a central gatekeeper in biopsy decision-making, it is not infallible. Clinically significant prostate cancer may therefore remain undetected, particularly in patients with elevated PSA density, adverse PSA kinetics, or MRI-occult disease. This narrative review synthesizes contemporary evidence on PSA interpretation, mpMRI performance, and biopsy strategy selection, highlighting the limitations of single-parameter approaches. We discuss the diagnostic yield and clinical implications of targeted, systematic, and combined biopsy techniques, emphasizing scenarios in which systematic sampling remains necessary despite negative or equivocal imaging findings. Emerging data support combined targeted and systematic biopsy as the most robust strategy for maximizing the detection of clinically significant disease while limiting overdiagnosis in most biopsy-naive and high-risk patients. By integrating PSA dynamics, prostate volume, imaging findings, and individual risk profiles, a structured, risk-adapted diagnostic pathway can be achieved. The proposed framework is intended as a conceptual, expert-derived clinical aid to support risk-adapted decision-making. It should be interpreted alongside established guidelines, and prospective validation in future studies is warranted.